Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 5:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,112 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Dyslipidaemia Clear all
Completed Phase 4 Interventional

Genetic Basis for Heterogeneity in Response of Plasma Lipids to Plant Sterols

NCT01131832
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Plant sterol, Placebo
Dietary Supplement
Lead sponsor
University of Manitoba
Other
Eligibility
30 Years to 75 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Beltsville, Maryland
Source: ClinicalTrials.gov public record
Updated May 8, 2017 · Synced Sep 4, 2026, 5:16 AM EDT
Active, not recruiting Not applicable Interventional

Church-based Health Intervention to Eliminate Racial Inequalities in Cardiovascular Health

NCT06065098
View directory record Official record
Conditions
Cardiovascular Diseases, Hypertension, Diabetes, Hypercholesterolemia
Interventions
Evidence-based interventions recommended by the 2019 ACC/AHA Guideline on the Primary Prevention of CVD
Behavioral
Lead sponsor
Tulane University
Other
Eligibility
40 Years and older
Enrollment
812 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Sep 4, 2026, 5:16 AM EDT
Completed Not applicable Interventional Results available

Combined Behavioral and Pharmacological Intervention for Cardiovascular Risk Reduction in Diabetic Patients

NCT00357955
View directory record Official record
Conditions
Diabetes, Hypertension, Dyslipidemia, Coronary Arteriosclerosis
Interventions
Behavioral counseling and peer support, Interactive Education, Role modeling, Pharmacologic case management
Behavioral · Procedure
Lead sponsor
Providence VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Nov 6, 2024 · Synced Sep 4, 2026, 5:16 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C (CLEAR Tranquility)

NCT03001076
View directory record Official record
Conditions
Hypercholesterolemia, Atherosclerosis, Statin Adverse Reaction
Interventions
Bempedoic acid, Ezetimibe, Placebo
Drug · Other
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Georgetown, Texas
Source: ClinicalTrials.gov public record
Updated May 10, 2020 · Synced Sep 4, 2026, 5:16 AM EDT
Completed Phase 4 Interventional Results available

A Multi-Risk Factor Strategy vs a Guideline-Based Approach in Achieving Blood Pressure and Lipid Goals in Hypertensives at Extra Risk

NCT00412113
View directory record Official record
Conditions
Dyslipidemia, Hypertension
Interventions
Amlodipine besylate, Amlodipine besylate/atorvastatin calcium single pill combination
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
21 Years and older
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
51
States / cities
Birmingham, Alabama • Mesa, Arizona • Garden Grove, California + 44 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2021 · Synced Sep 4, 2026, 5:16 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Text Messaging to Promote Walking Among Latino Adults at Risk for Peripheral Arterial Disease

NCT02622282
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Text Messages, Phone Calls, Handout
Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
50 Years and older
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Wichita, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 1, 2017 · Synced Sep 4, 2026, 5:16 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Epanova® Compared to Lovaza® In a Pharmacokinetic, Single-dose, Evaluation

NCT01208961
View directory record Official record
Conditions
Severe Hypertriglyceridemia
Interventions
Epanova (4 g) and Lovaza (4 g), Lovaza (4 g) and Epanova (4 g)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 14, 2015 · Synced Sep 4, 2026, 5:16 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Social Needs Screening and Chronic Diseases Study (WE CARE)

NCT06903897
View directory record Official record
Conditions
Hyperlipidemias, Diabetes, Depression, Pediatric Asthma, Hypertension
Interventions
WE CARE SDOH System, Standard Pediatric Care
Other
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
Not listed
Enrollment
68,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
3
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 4, 2026, 5:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Soy Bread on Markers of Bone Metabolism and Cardiovascular Disease

NCT00366860
View directory record Official record
Conditions
Osteoporosis, Cardiovascular Diseases
Interventions
Soy bread
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
50 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 1, 2014 · Synced Sep 4, 2026, 5:16 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Point-of-Care Testing (POCT) Detection and Management of Metabolic Syndrome in Patients With Mental Illness

NCT02029989
View directory record Official record
Conditions
Hyperlipidemia, Diabetes, Hypertension
Interventions
Glucose and lipids, Glycosylated Hemoglobin A1c, Blood Pressure and Heart Rate, Body mass index, Waist and Hip circumference, Comprehensive Medication Management
Device · Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 64 Years
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Duluth, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 3, 2024 · Synced Sep 4, 2026, 5:16 AM EDT
Completed Phase 2 Interventional Results available

Monthly And Twice Monthly Subcutaneous Dosing Of PF-04950615 (RN316) In Hypercholesterolemic Subjects On A Statin

NCT01592240
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
PBO, 200mg PF-04950615 (RN316), 300mg PF-04950615 (RN316), PF-04950615
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
74
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tucson, Arizona + 59 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2017 · Synced Sep 4, 2026, 5:16 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) in Participants With Hyperlipoproteinemia(a) and Cardiovascular Disease

NCT03070782
View directory record Official record
Conditions
Elevated Lipoprotein(a), Cardiovascular Disease
Interventions
ISIS 681257, Placebo
Drug
Lead sponsor
Akcea Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
22
States / cities
Cottonwood, Arizona • Huntington Beach, California • La Jolla, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2020 · Synced Sep 4, 2026, 5:16 AM EDT
Completed Phase 2 Interventional

Trial of ARI-3037MO to Reduce Triglyceride Levels in Adults With Severe (≥500 mg/dl) Hypertriglyceridemia

NCT02250105
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
ARI-3037MO, Placebo
Drug
Lead sponsor
Arisaph Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
5
States / cities
Tustin, California • Louisville, Kentucky • Auburn, Maine + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2016 · Synced Sep 4, 2026, 5:16 AM EDT
Completed Phase 3 Interventional Results available

Effects of Pioglitazone on High-density Lipoprotein (HDL) Function in Persons With Diabetes

NCT01156597
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
pioglitazone
Drug
Lead sponsor
University of Miami
Other
Eligibility
35 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 20, 2014 · Synced Sep 4, 2026, 5:16 AM EDT
Not listed No phase listed Observational

Impact of a Chewable Plant Sterol Supplement on LDL-C in A Real-World Setting

NCT04642742
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Chewable plant sterol
Dietary Supplement
Lead sponsor
Piper Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Los Altos, California
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Sep 4, 2026, 5:16 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Mechanisms and Interventions to Address Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans Men

NCT04922424
View directory record Official record
Conditions
Hypertension, Hyperlipidemias
Interventions
Atorvastatin, placebo
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 35 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 2, 2022 · Synced Sep 4, 2026, 5:16 AM EDT
Completed Phase 3 Interventional Results available

LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2

NCT01763866
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Evolocumab, Ezetimibe, Placebo to Evolocumab, Placebo to Ezetimibe, Atorvastatin, Rosuvastatin, Simvastatin
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
2,067 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
65
States / cities
Birmingham, Alabama • Glendale, Arizona • Tucson, Arizona + 58 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Sep 4, 2026, 5:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Interaction of Epanova on Warfarin Pharmacokinetic and Anticoagulant Activity and Comparison of the Effects of Epanova and Lovaza on Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) After Low-fat Meals

NCT01431690
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
warfarin, omefas, omega-3-acid ethyl esters
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 23, 2015 · Synced Sep 4, 2026, 5:16 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Metabolism And Health Effects Of Citrus Limonoids in Hypercholesterolemic Humans

NCT02011789
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Citrus Limonoid Beverage, Placebo beverage
Dietary Supplement
Lead sponsor
USDA, Western Human Nutrition Research Center
Federal
Eligibility
20 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Dec 12, 2013 · Synced Sep 4, 2026, 5:16 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Online Trial Examining Validity of the Shared Decision Making Process Survey With Video Vignettes

NCT04317274
View directory record Official record
Conditions
Colorectal Cancer, High Cholesterol
Interventions
Good high cholesterol video, Poor high cholesterol video, Good colon cancer screening video, Poor colon cancer screening video
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
401 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 4, 2024 · Synced Sep 4, 2026, 5:16 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus

NCT00760344
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
SYR-472, Placebo, Sitagliptin
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
105
States / cities
Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 102 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2016 · Synced Sep 4, 2026, 5:16 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Homozygous Familial Hypercholesterolemia

NCT04659863
View directory record Official record
Conditions
Familial Hypercholesterolemia - Homozygous
Interventions
Inclisiran, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 17 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Sep 4, 2026, 5:16 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Fish Oil Study for High Triglyceride Levels in Children

NCT00915902
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
Omega-3-acid ethyl esters, Placebo
Drug
Lead sponsor
Babu Balagopal
Other
Eligibility
10 Years to 17 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
3
States / cities
Wilmington, Delaware • Baltimore, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Sep 4, 2026, 5:16 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Evaluate Safety and Efficacy of AEGR-733 and Atorvastatin vs Atorvastatin Monotherapy in Hypercholesterolemia

NCT00690443
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Atorvastatin, AEGR-733
Drug
Lead sponsor
Aegerion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
5
States / cities
Pinellas Park, Florida • Edina, Minnesota • Mogadore, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2018 · Synced Sep 4, 2026, 5:16 AM EDT